Perceptive Advisors LLC recently announced the acquisition of new stake in Leap Therapeutics Inc. (NASDAQ:LPTX). The institutional investor has increased its shareholding in the Healthcare company by 26.02% to 8.48 million shares with purchase of 1.75 million shares. This fresh investment now brings its stake to 23.68% valued currently at $20.09 million. In addition, Sio Capital Management LLC raised its holdings by 0.62 million to 1.1 million shares. And Sphera Funds Management Ltd. has lifted its position to 0.6 million shares – to 0.6 million shares.
With over 0.56 million Leap Therapeutics Inc. (LPTX) shares trading Wednesday and a closing price of $2.07 on the day, the dollar volume was approximately $1.16 million. The shares have shown a negative weekly performance of -0.96% and its price on 07/08/20 gained nearly 3.50%. Currently, there are 31.63M common shares owned by the public and among those 21.26M shares have been available to trade.
Insiders at the company have transacted a total of 1 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 1 of these insider trades were purchases, accounting for 1,750,000 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Leap Therapeutics Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.48 million shares of the company’s stock, all valued at over $1.13 million. The company has a total holdings of about 1.33% of the shares outstanding. Vanguard Extended Market Index Fu has total holdings of 0.17 million shares valued at over $0.4 million and representing 0.47% of the shares outstanding. Fidelity Extended Market Index Fu has total holdings to over 59536.0 shares at a value of $0.14 million. Fidelity Extended Market Index Fu now owns shares totaling to 0.17% of the shares outstanding.
Shares of Leap Therapeutics Inc. (NASDAQ: LPTX) opened at $2.05, up $0.05 from a prior closing price of $2.00. However, the script later closed the day at $2.07, up 3.50%. The company’s stock has a 5-day price change of -0.96% and 35.29% over the past three months. LPTX shares are trading 84.82% year to date (YTD), with the 12-month market performance up to 1.22% higher. It has a 12-month low price of $0.57 and touched a high of $3.18 over the same period. Currently, 0.56 million shares have been traded, compared to an average intraday trading volume of 542.46K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.42%, -8.86%, and 22.59% respectively.
Institutional ownership of Leap Therapeutics Inc. (NASDAQ: LPTX) shares accounts for 30.90% of the company’s 31.63M shares outstanding. Mutual fund holders own 33.87%, while other institutional holders and individual stakeholders account for 61.00% and 2.39% respectively.
It has a market capitalization of $120.00M and a beta (3y monthly) value of 1.95. The stock’s earnings-per-share (ttm) stands at -$1.57. The company has a Quick Ratio of 2.80 with the debt-to-equity ratio at 0.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.92% over the week and 10.51% over the month.
Analysts forecast that Leap Therapeutics Inc. (LPTX) will achieve an EPS of -$0.18 for the current quarter, -$0.18 for the next quarter and -$0.69 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.25 while analysts give the company a high EPS estimate of -$0.11. Comparatively, EPS for the current quarter was -$0.37 a year ago. Earnings per share for the fiscal year are expected to increase by 10.00%, and 28.90% over the next financial year. EPS should grow at an annualized rate of -2.49% over the next five years, compared to -12.40% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by several brokerage firm advisors rate Leap Therapeutics Inc. (LPTX) as a “Strong Buy” at a consensus score of 1.60.
Looking at the support for the LPTX, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on June 29, 2020, with the firm’s price target at $6. Robert W. Baird coverage for the Leap Therapeutics Inc. (LPTX) stock in a research note released on February 11, 2020 offered a Outperform rating with a price target of $6. Raymond James was of a view on November 15, 2019 that the stock is Mkt Perform, while Raymond James gave the stock Outperform rating on September 13, 2019. Ladenburg Thalmann on their part issued Buy rating on March 07, 2017.